retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Retatrutide vs Tirzepatide: Comprehensive Comparison
Description
a 92% reduction in diabetes deaths, 60% reduction in cancer deaths, 56% reduction in coronary artery disease deaths and 40% reduction in all-cause mortality was demonstrated in a retrospective matched cohort study of obese individuals undergoing bariatric surgery
Gut-brain axis signaling: The gut communicates with the brain through hormones such as GLP-1, peptide YY (PYY), and cholecystokinin (CCK)
Incorporate whole grains, fruits, and vegetables into your meals, and limit simple carbs and empty calories
Retatrutide also targets glucagon receptors
